Venetoclax in Patients With MDS or AML in Relapse After AHSCT

AML Clinical Trial

Official title:

A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML (Blasts < 30%) in Relapse After Allohematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05226455
• Other study ID #: VENTOGRAFT
• Secondary ID: 2021-000632-56
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 23, 2022
• Est. completion date: March 1, 2026

Study information

• Verified date: April 2024
• Source: Groupe Francophone des Myelodysplasies
• Contact: Fatiha CHERMAT
• Phone: 01 71 20 70 59
• Email: fatiha.chermat-ext[@]aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study to assess venetoclax + azacitidine and donor lymphocyte infusion (DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with blasts < 30% in relapse after allohematopoietic stem cell transplantation (AHSCT).

Description:

A phase I-II study to assess venetoclax + azacitidine and donor lymphocyte infusion (DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with blasts < 30% in relapse after allohematopoietic stem cell transplantation (AHSCT).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 55
• Est. completion date: March 1, 2026
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Documented relapse of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with marrow blasts < 30% (with white blood cells (WBC) < 15000/mm3), after allohematopoietic stem cell transplantation.

Relapse of MDS or AML is defined as :

• Return to pretreatment bone marrow blast percentage
• Decrement of at least 50% from maximum remission

2. Age = 18 years.

3. Eastern Cooperative Oncology Group (ECOG) performance status = 2.

4. Patient must have adequate organ function:

• Serum creatinine < 2 mg/dL or calculated creatinine clearance = 30 mL/min for patients with creatinine levels > 1.5 times Upper Limit of Normal
• Serum total bilirubin = 2.5 times Upper Limit of Normal or direct bilirubin = Upper Limit of Normal for patients with total bilirubin levels = 2 mg/d
• Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 2.5 times Upper Limit of Normal
• Alkaline phosphatase = 5 times Upper Limit of Normal (if > 2.5 times Upper Limit of Normal, then liver fraction should be = 2.5 times Upper Limit of Normal).

5. Patient not refractory to platelet transfusions.

6. Female subject of childbearing potential must practice at least one protocol specified method of birth control, starting on Study Day 1 through at least 30 days after the last dose of venetoclax or 3 months after the last dose of azacitidine.

Not being of childbearing potential is defined as:

• Age > 55 years with no menses for 12 or more months without an alternative medical cause, or
• Age = 55 years with no menses for 12 or more months without an alternative medical cause AND an Follicle Stimulating Hormone (FSH) level > 40 IU/L, or
• Permanent surgical sterility (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

7. Female subjects of childbearing potential must have negative results for pregnancy

test performed:

• At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and
• Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results. Female subjects who are not of childbearing potential at Screening do not require pregnancy testing.

8. Male subjects sexually active with female partner(s) of childbearing potential, must agree from first dose of study drug(s) through at least 30 days after the last dose of venetoclax or 3 months after the last dose of azacitidine, whichever is later, to practice the protocol specified contraception.

9. Patient is available for periodic blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study.

10. Patient has the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study.

11. Patient is able to swallow capsules.

Exclusion Criteria:

1. Patient has active and uncontrolled infection.

2. Patient has active acute or chronic Graft-versus-Host-Disease (GVHD).

3. Patient receives more than 1mg/kg/day prednisolone.

4. Patient has uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance.

5. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug.

6. Patient has known human immunodeficiency virus (HIV) infection or HIV-related malignancy.

7. Patient has clinically active hepatitis B or hepatitis C infection.

8. Patient has a known allergy or hypersensitivity to any component of venetoclax or azacitidine.

9. Patient with a "currently active" second malignancy, other than non-melanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for > 2 years or are considered by their physician to be at less than 30% risk of relapse.

10. Patient has received growth factors such as erythropoietin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF) or has received non cytotoxic agents (including low dose oral chemotherapy) in the 30 days before inclusion. In case of previous cytotoxic treatment, an interval of 3 months is required.

11. Patient is on any systemic steroids that have not been stabilized to the equivalent of = 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs.

12. Patients with clinical evidence of Central Nervous System leukemia.

13. Patient has a history of Gastrointestinal surgery or other procedures that might interfere with the absorption or swallowing of the study drugs.

14. Subject has received strong or moderate CYP3A (Cytochrome P450, family 3, subfamily A) inhibitors within 3 days prior to the first dose of study drug.

15. Patient is unable to take and/or tolerate oral medications on a continuous basis.

16. Patient is pregnant or breastfeeding within the projected duration of the study.

17. Subject has a malabsorption syndrome or other condition that precludes an enteral route of administration.

18. Absence of social security.

Related Conditions & MeSH terms

• AML
• MDS
• Recurrence

Intervention

Drug:
• venetoclax + azacitidine +/- donor lymphocyte infusion
Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)

Locations

Country	Name	City	State
France	CHU d'Amiens Picardie - Site sud	Amiens
France	CHU d'Angers	Angers
France	CHU de Grenoble	Grenoble
France	Hôpital Dupuytren	Limoges
France	Hôpital Saint-Eloi	Montpellier
France	CHU Hôtel Dieu	Nantes
France	Hôpital l'Archet I	Nice
France	Hôpital Saint louis	Paris
France	CHU de Haut-Lévèque	Pessac
France	Centre Hospitalier Lyon-Sud	Pierre-Bénite
France	Centre Henri Becquerel	Rouen
France	Institut de Cancérologie de la Loire Lucien Neuwirth	Saint-Priest-en-Jarez
France	IUCT Oncopole	Toulouse
France	Hôpital Brabois	Vandœuvre-lès-Nancy

Sponsors (2)

Lead Sponsor	Collaborator
Groupe Francophone des Myelodysplasies	AbbVie

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Correlation between patient overall mutational status before and after treatment	Mutational analysis performed by NGS (next-generation sequencing) at screening and then at each protocol evaluation (post 4, 6 and 8 cycles of venetoclax + azacitidine and at end of study)	At 42 months (at end of study)
Other	Prognostic impact of Minimal Residual Disease (MRD) on outcome	Minimal Residual Disease (MRD) assessment by flow cytometry and allelic variant frequency (VAF) of baseline mutations	At 42 months (at end of study)
Primary	Phase I: Dose-finding study	Evaluation of Dose-limiting toxicity (DLT) to determine the optimal dose level in terms of both toxicity and safety for venetoclax + azacitidine	At the end of cycle 1 of venetoclax + azacitidine (each cycle is 28 days)
Primary	Phase II: Overall improvement rate of venetoclax + azacitidine +/- DLI	Response assessment performed according to modified IWG (International Working Group) 2006 criteria for myelodysplastic syndrome and to European Leukemia Net criteria for acute myeloid leukemia	After 8 cycles of venetoclax + azacitidine (each cycle is 28 days)
Secondary	Toxicity assessment	Adverse events analyzed by frequency, NCI CTCAE 5.0 grade, and causality	At 42 months (at end of study)
Secondary	Graft-versus-Host-Disease (GVHD) rate	Acute and chronic graft-versus-host-disease (GVHD) rate assessment (graft-versus-host events analyzed by frequency and grade)	At 42 months (at end of study)
Secondary	Duration of response	Duration of response defined as time from the date of the first observed response (complete or partial) to the date of first subsequent documented disease progression or relapse or death	At 42 months (at end of study)
Secondary	Overall survival	Overall Survival defined as time from the date of the first dose of venetoclax to the date of death or end of study	At 42 months (at end of study)
Secondary	Progression-free survival	Progression-free Survival for patients with at least a partial response defined as time from the date of the first dose of venetoclax to the date of the first documented disease progression or relapse or death	At 42 months (at end of study)
Secondary	Event-free survival	Event-free Survival defined as time from the date of the first dose of venetoclax to the date of earliest disease progression or death	At 42 months (at end of study)